慢性鼻副鼻腔炎市場- 世界の産業規模、シェア、動向、機会、予測、疾患表現型別、治療タイプ別、流通チャネル別、地域別、競合別セグメント、2020-2030年

慢性鼻副鼻腔炎の世界市場規模は2024年に26億2,000万米ドルで、予測期間には39億9,000万米ドルに達し、2030年までのCAGRは7.23%と予測されています。

世界の慢性鼻副鼻腔炎市場は、流行し、持続する慢性鼻副鼻腔炎（CRS）の状態に対処することに特化した、ダイナミックで進化するヘルスケア分野です。CRSは鼻や副鼻腔に影響を及ぼす慢性炎症性疾患で、鼻づまり、顔面痛、嗅覚障害などの症状を引き起こします。この市場には、症状の緩和、炎症の軽減、罹患者の全体的なQOLの向上を目的とした医薬品、医療機器、治療方法が幅広く含まれています。

慢性鼻副鼻腔炎世界市場の成長促進要因のひとつは、世界のCRS発症率の増加です。環境汚染物質、アレルギー、ライフスタイルの変化などの要因がCRSの有病率上昇に寄与しており、効果的な治療を求める患者が多数存在しています。ヘルスケアプロバイダーや製薬会社は、CRSを管理し患者に長期的な緩和を提供するために、生物学的製剤、副腎皮質ステロイド、抗生物質を含む革新的な治療法を導入する研究開発に積極的に取り組んでいます。

市場促進要因

慢性鼻副鼻腔炎の有病率の上昇

主な市場課題

高い治療費

主要市場動向

生物学的治療

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の慢性鼻副鼻腔炎市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 疾患表現型別（非好酸球性慢性副鼻腔炎、好酸球性慢性副鼻腔炎、感染性慢性副鼻腔炎、アレルギー性真菌性副鼻腔炎、その他）
  • 治療の種類別（医療機器、医薬品、点鼻薬、ステロイド点鼻薬、手術、その他）
  • 流通チャネル別（病院薬局、小売薬局、オンライン薬局）
  • 地域別
  • 企業別（2024）
• 市場マップ
  • 疾患表現型別
  • 治療の種類別
  • 流通チャネル別
  • 地域別

第5章 アジア太平洋地域の慢性鼻副鼻腔炎市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 疾患表現型別
  • 治療の種類別
  • 流通チャネル別
  • 国別
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第6章 欧州の慢性鼻副鼻腔炎市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第7章 北米の慢性鼻副鼻腔炎市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第8章 南米の慢性鼻副鼻腔炎市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第9章 中東・アフリカの慢性鼻副鼻腔炎市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第10章 市場力学

• 促進要因
• 課題

第11章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第12章 世界の慢性鼻副鼻腔炎市場：SWOT分析

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Lyra Therapeutics
• Novartis AG
• Medtronic plc
• GlaxoSmithKline plc
• AstraZeneca Plc
• Sanofi AG
• Dr. Reddy's Laboratories Ltd.
• Stryker Corporation
• Bayer AG
• Smith & Nephew Plc

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Chronic Rhinosinusitis Market was valued at USD 2.62 Billion in 2024 and is expected to reach USD 3.99 Billion in the forecast period with a CAGR of 7.23% through 2030. The Global Chronic Rhinosinusitis Market is a dynamic and evolving healthcare sector dedicated to addressing the prevalent and persistent condition of chronic rhinosinusitis (CRS). CRS is a chronic inflammatory disease affecting the nasal and sinus passages, leading to symptoms such as nasal congestion, facial pain, and impaired sense of smell. This market encompasses a wide range of pharmaceuticals, medical devices, and treatment modalities aimed at alleviating symptoms, reducing inflammation, and improving the overall quality of life for affected individuals.

One of the primary drivers of growth in the Global Chronic Rhinosinusitis Market is the increasing incidence of CRS worldwide. Factors such as environmental pollutants, allergies, and lifestyle changes contribute to the rising prevalence of this condition, creating a substantial patient pool seeking effective treatments. Healthcare providers and pharmaceutical companies are actively engaged in research and development efforts to introduce innovative therapies, including biologics, corticosteroids, and antibiotics, to manage CRS and provide long-term relief to patients.

Key Market Drivers

Rising Prevalence of Chronic Rhinosinusitis

Chronic Rhinosinusitis (CRS), characterized by prolonged inflammation of the nasal and sinus passages, has seen a notable increase in prevalence globally, significantly impacting the healthcare landscape. This rise is attributed to various factors, including environmental pollution, lifestyle changes, and heightened awareness leading to more frequent diagnoses.

Environmental pollution plays a substantial role in the escalating incidence of CRS. Exposure to air pollutants, particularly particulate matter (PM), has been correlated with increased CRS prevalence and severity. Studies indicate that for each unit increase in PM2.5, there is a 1.89-fold increased risk in the proportion of CRS patients requiring sinus surgery. Additionally, research has shown that long-term exposure to PM2.5 is associated with the development of CRS, underscoring the impact of environmental factors on this condition.

Key Market Challenges

High Treatment Costs

High treatment costs stand out as a significant hindrance in the Global Chronic Rhinosinusitis (CRS) Market, impacting both patients and healthcare systems alike. Chronic Rhinosinusitis, a persistent inflammatory condition of the nasal and sinus passages, requires comprehensive treatment approaches, including diagnostic tests, pharmaceuticals, surgical interventions, and long-term management. The cost associated with these aspects of care can present substantial challenges. One of the primary concerns related to high treatment costs is the financial burden it places on patients. Diagnostic procedures such as computed tomography (CT) scans and magnetic resonance imaging (MRI) can be expensive, and these costs are often not fully covered by insurance plans.

Key Market Trends

Biologic Therapies

Biologic therapies have emerged as a powerful and transformative force in boosting the Global Chronic Rhinosinusitis (CRS) Market. Chronic Rhinosinusitis, characterized by persistent inflammation of the nasal and sinus passages, has historically presented a challenging treatment landscape. However, biologic therapies, including monoclonal antibodies and other targeted drugs, have revolutionized the management of CRS and are driving significant growth in the market.

One of the key factors contributing to the success of biologic therapies is their precision in addressing the underlying inflammatory pathways and immune responses that drive CRS. These therapies are designed to specifically target and inhibit molecules or receptors involved in the inflammatory cascade, thereby reducing symptoms and improving the quality of life for CRS patients. By directly tackling the root causes of inflammation, biologics offer a highly effective and targeted approach to treatment.

Key Market Players

Lyra Therapeutics

Novartis AG

Medtronic plc

GlaxoSmithKline plc

AstraZeneca Plc

Sanofi AG

Dr. Reddy's Laboratories Ltd.

Stryker Corporation

Bayer AG

Smith & Nephew Plc

Report Scope:

In this report, the Global Chronic Rhinosinusitis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Chronic Rhinosinusitis Market, By Disease Phenotype:

• Non-Eosinophilic Chronic Rhinosinusitis
• Eosinophilic Chronic Rhinosinusitis
• Infectious Chronic Rhinosinusitis
• Allergic Fungal Rhinosinusitis
• Others

Chronic Rhinosinusitis Market, By Treatment Type

• Medical Devices
• Drugs
• Nasal Drops
• Steroid Nasal Sprays
• Surgery
• Others

Chronic Rhinosinusitis Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Chronic Rhinosinusitis Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Chronic Rhinosinusitis Market.

Available Customizations:

Global Chronic Rhinosinusitis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Chronic Rhinosinusitis Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Disease Phenotype (Non-Eosinophilic Chronic Rhinosinusitis, Eosinophilic Chronic Rhinosinusitis, Infectious Chronic Rhinosinusitis, Allergic Fungal Rhinosinusitis, Others)
  • 4.2.2. By Treatment Type (Medical Devices, Drugs, Nasal Drops, Steroid Nasal Sprays, Surgery, Others)
  • 4.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 4.2.4. By Region
  • 4.2.5. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Disease Phenotype
  • 4.3.2. By Treatment Type
  • 4.3.3. By Distribution Channel
  • 4.3.4. By Region

5. Asia Pacific Chronic Rhinosinusitis Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease Phenotype
  • 5.2.2. By Treatment Type
  • 5.2.3. By Distribution Channel
  • 5.2.4. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Chronic Rhinosinusitis Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Disease Phenotype
      • 5.3.1.2.2. By Treatment Type
      • 5.3.1.2.3. By Distribution Channel
  • 5.3.2. India Chronic Rhinosinusitis Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Disease Phenotype
      • 5.3.2.2.2. By Treatment Type
      • 5.3.2.2.3. By Distribution Channel
  • 5.3.3. Australia Chronic Rhinosinusitis Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Disease Phenotype
      • 5.3.3.2.2. By Treatment Type
      • 5.3.3.2.3. By Distribution Channel
  • 5.3.4. Japan Chronic Rhinosinusitis Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Disease Phenotype
      • 5.3.4.2.2. By Treatment Type
      • 5.3.4.2.3. By Distribution Channel
  • 5.3.5. South Korea Chronic Rhinosinusitis Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Disease Phenotype
      • 5.3.5.2.2. By Treatment Type
      • 5.3.5.2.3. By Distribution Channel

6. Europe Chronic Rhinosinusitis Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease Phenotype
  • 6.2.2. By Treatment Type
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Chronic Rhinosinusitis Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease Phenotype
      • 6.3.1.2.2. By Treatment Type
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Germany Chronic Rhinosinusitis Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease Phenotype
      • 6.3.2.2.2. By Treatment Type
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Spain Chronic Rhinosinusitis Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease Phenotype
      • 6.3.3.2.2. By Treatment Type
      • 6.3.3.2.3. By Distribution Channel
  • 6.3.4. Italy Chronic Rhinosinusitis Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Disease Phenotype
      • 6.3.4.2.2. By Treatment Type
      • 6.3.4.2.3. By Distribution Channel
  • 6.3.5. United Kingdom Chronic Rhinosinusitis Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Disease Phenotype
      • 6.3.5.2.2. By Treatment Type
      • 6.3.5.2.3. By Distribution Channel

7. North America Chronic Rhinosinusitis Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease Phenotype
  • 7.2.2. By Treatment Type
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Chronic Rhinosinusitis Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease Phenotype
      • 7.3.1.2.2. By Treatment Type
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Mexico Chronic Rhinosinusitis Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease Phenotype
      • 7.3.2.2.2. By Treatment Type
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. Canada Chronic Rhinosinusitis Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease Phenotype
      • 7.3.3.2.2. By Treatment Type
      • 7.3.3.2.3. By Distribution Channel

8. South America Chronic Rhinosinusitis Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease Phenotype
  • 8.2.2. By Treatment Type
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Chronic Rhinosinusitis Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease Phenotype
      • 8.3.1.2.2. By Treatment Type
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. Argentina Chronic Rhinosinusitis Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease Phenotype
      • 8.3.2.2.2. By Treatment Type
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Colombia Chronic Rhinosinusitis Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease Phenotype
      • 8.3.3.2.2. By Treatment Type
      • 8.3.3.2.3. By Distribution Channel

9. Middle East and Africa Chronic Rhinosinusitis Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease Phenotype
  • 9.2.2. By Treatment Type
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Chronic Rhinosinusitis Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease Phenotype
      • 9.3.1.2.2. By Treatment Type
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Saudi Arabia Chronic Rhinosinusitis Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease Phenotype
      • 9.3.2.2.2. By Treatment Type
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. UAE Chronic Rhinosinusitis Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease Phenotype
      • 9.3.3.2.2. By Treatment Type
      • 9.3.3.2.3. By Distribution Channel

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Chronic Rhinosinusitis Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Lyra Therapeutics
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. Novartis AG
• 14.3. Medtronic plc
• 14.4. GlaxoSmithKline plc
• 14.5. AstraZeneca Plc
• 14.6. Sanofi AG
• 14.7. Dr. Reddy's Laboratories Ltd.
• 14.8. Stryker Corporation
• 14.9. Bayer AG
• 14.10.Smith & Nephew Plc

15. Strategic Recommendations

16. About Us & Disclaimer